Stephens Investment Management Group LLC Decreases Holdings in Hologic, Inc. $HOLX

Stephens Investment Management Group LLC reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 5.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 578,276 shares of the medical equipment provider’s stock after selling 35,381 shares during the period. Stephens Investment Management Group LLC’s holdings in Hologic were worth $39,028,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its stake in shares of Hologic by 294.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after buying an additional 8,227,318 shares during the last quarter. Invesco Ltd. raised its position in Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after acquiring an additional 3,505,828 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Hologic by 1.7% in the second quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock valued at $378,209,000 after purchasing an additional 97,142 shares in the last quarter. Black Creek Investment Management Inc. grew its position in shares of Hologic by 26.1% in the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after purchasing an additional 832,444 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Hologic by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 3,090,306 shares of the medical equipment provider’s stock worth $201,364,000 after purchasing an additional 66,453 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on HOLX. Stephens cut Hologic from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $78.00 to $76.00 in a report on Wednesday, October 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Finally, BNP Paribas downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective on the stock. in a research note on Friday, November 21st. Three analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Hologic presently has an average rating of “Hold” and a consensus price target of $79.29.

Hologic Trading Down 0.1%

Shares of HOLX opened at $74.98 on Friday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $75.34. The firm has a market capitalization of $16.71 billion, a P/E ratio of 30.23, a price-to-earnings-growth ratio of 2.13 and a beta of 0.69. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50. The stock’s fifty day simple moving average is $74.73 and its 200 day simple moving average is $70.17.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The firm’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.01 earnings per share. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.